依類型篩選 全部顯示 頁面 解決方案 專業服務 報告 新聞 Webinars 活動 地點 問與答 案例研究 白皮書 Filter By 任何 頁面 解決方案 專業服務 報告 新聞 Webinars 活動 地點 問與答 案例研究 白皮書 2022/7/21 Webinar Evolution of cell & gene therapy in China: the case for universal CAR-T JIE CHEN CHIEF MEDICAL OFFICER, BIOHENG 觀看 2019/12/10 新聞 Novotech CRO sees changing landscape in Hemato-Oncology at ASH 2019 Novotech, the Asia-Pacific CRO, attends the American Society of Hematology conference in Orla 報告 2021/8/27 報告 Clinical trial landscape of B-cell lymphoma in asia-pacific Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and the most aggressive subtype constituting nearly 70% of B-Cell Lymphomas in Asia. 下載 2022/10/12 報告 陣發性夜間血紅素尿症 (Paroxysmal nocturnal hemoglobinuria,PNH) – 亞太地區 – 臨床試驗狀 況。 根據估計,西方地區國家每年每百萬人有 1- 2 起病例患有 PNH,而亞洲地區每年每百萬人約 10 起病例,其中又以中國和印度的 PNH 病例最多。 下載 2022/5/26 報告 Follicular lymphoma - Asia pacific - clinical Trial landscape Owing to its large population base, Asia may account for over 40% of the estimated global incidence of Follicular Lymphoma, with China, Japan and India collectively contributing to over a quarter o 下載 2021/9/17 報告 Clinical trial landscape of diabetes (type 2) in asia-pacific Diabetes, which is endemic in most Western countries, is now seeing a surge in developing nations across Asia due to aging, urbanization, and changing dietary habits. 下載 2021/8/20 報告 Clinical trial landscape of t-cell lymphomas in asia-pacific T-cell lymphomas (TCLs) are types of non-Hodgkin’s lymphoma (NHL) that affect T lymphocytes. 下載 2022/8/22 報告 Diffuse large b-cell Lymphoma – Asia Pacific – Clinical trial landscape Asia accounted for nearly 70% of the global incidence of DLBCL in 2020, with Mainland China, India, and Japan contributing to a third of all DLBCL cases worldwide. 下載 2021/10/14 報告 Clinical trial landscape Of cll in asia-pacific CLL is one of the most common forms of leukaemia, with the Asia Pacific region showing increasing incidence. China and South Korea are among the Asian locations showing the greatest incidence. 下載 2022/5/30 Webinar 美國和中國的發展和法規策略 演講者和參加小組討論專家們的工作經歷: 觀看 載入更多